Drugs to lose weight: the WHO defined how they can be used by children and adolescents

The World Health Organization released new guidelines for managing obesity in children and adolescents, addressing growing concerns about the use of weight loss drugs like GLP-1 analogs. The WHO highlights that 93.1 million children aged 5 to 14 and 80.6 million adolescents aged 15 to 24 live with obesity, a figure projected to reach 250 million by 2030 amid tripling global obesity rates since 1975.
The guidelines recommend an interdisciplinary approach focusing on lifestyle modifications—diet, physical activity, and behavioral changes—as the primary basis for obesity care in children and adolescents. For adolescents with obesity and associated complications (such as type 2 diabetes or insulin resistance), medication use is suggested only if structured, supervised lifestyle interventions have failed over at least six months.
Regarding GLP-1 analogs like semaglutide and tirzepatide, which are approved in Argentina for obesity management starting at different ages (12 for semaglutide, 18 for tirzepatide), there is growing use among adolescents. A study of US pharmacy data indicated a nearly 600% increase in sales of these analogs for adolescents between 2020 and 2023.
The WHO expressed concern about starting these medications early in children, noting a lack of evidence regarding their long-term effects on growth, development, and mental health, especially when compared to addressing environmental and dietary factors first. The recommendations emphasize that any drug prescription must occur in a multidisciplinary setting with strict monitoring of potential adverse effects and long-term follow-up.

* The World Health Organization disseminated new guidelines for managing obesity in children and adolescents.
* 93.1 million children aged 5 to 14 and 80.6 million adolescents aged 15 to 24 live with obesity.
* The total figure for these age groups is projected to rise to 250 million by 2030.
* The UN recommends an interdisciplinary approach to address obesity, which impacts non-communicable diseases like diabetes and cardiovascular events.
* GLP-1 analogs, such as semaglutide and tirzepatide, mimic the effects of the appetite-regulating hormone GLP-1.
* In Argentina, semaglutide is authorized for obesity management from age 12, and tirzepatide from age 18.
* A study detected an increase of almost 600% in the sale of GLP-1 analogs for adolescents in the United States between 2020 and 2023.
* The WHO recommends using these drugs for adolescents aged 10 to 19 only if obesity is present and complications exist, and only after a supervised multimodal lifestyle modification program has failed.
* For children under 10 years old, the recommendation is no use of obesity medications in boys under 9 years old due to a lack of sufficient studies on long-term effects.
* The WHO warns that drug treatment must be prescribed after evaluation of physical development, psychological stability, and adherence to healthy habits.

The narrative frames the discussion around the tension between immediate symptom management (using trendy drugs) and long-term developmental health for vulnerable populations. The core conflict is established by the WHO’s caution against prioritizing pharmacotherapy over fundamental lifestyle and environmental modifications, especially in growing bodies. This positions pharmacological intervention not as a standalone solution but as an ancillary tool requiring rigorous justification, which the organization admits currently lacks in many areas.
The growth of GLP-1 analog sales among adolescents, starkly juxtaposed with the WHO's strong caveats regarding developmental risks, creates a tension between market adoption and clinical caution. This suggests a dynamic where commercial interests and growing patient demand are outpacing robust long-term safety data for this specific demographic. The specialist’s point that stopping medication does not necessarily reverse weight gain because chronic disease persists highlights that the treatment's efficacy may be intertwined with addressing the underlying systemic issues of obesity, rather than being a singular fix.
The pattern observed is a trajectory where emerging, effective treatments enter the market rapidly, often outpacing the establishment of longitudinal safety evidence for specific subgroups, particularly minors. The focus shifts from treating an isolated symptom to managing a chronic, multifaceted condition requiring holistic, developmental consideration. The implication is that the drive toward pharmacological solutions risks externalizing the long-term costs onto developing bodies by neglecting the necessary interdisciplinary foundation of physical activity and family support.
Bridge Questions: What specific methodologies are required to generate the long-term evidence needed to confidently guide medication use in growing adolescents? How can health systems balance the pressure for cost-effective interventions with the principle of safeguarding developmental timelines? If lifestyle modification is deemed to have failed, what concrete, measurable markers must be present to justify moving toward pharmacological intervention?